Alzamend Neuro Inc

ALZN • Biotechnology

$1.29

▼ -0.01 (-0.77%)

Current price

EarningsLatest report: Jul 31, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$5.78M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0Healthy liquidity · 1.31Weak profitability

Financial data as of: Jul 31, 2026, 12:00 AM UTCLast earnings update: Jul 31, 2026, 12:00 AM UTCLast profile update: Sep 11, 2026, 12:12 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.29

Change-0.77%

Shares Out4.48M

Market Cap$5.78M

Enterprise Value$-1.81M

52W Range0.84 - 2.68

Beta0.19

P/E-0.64

P/B1.00

P/FCF-0.84

EV/EBITDA0.20

EV/FCF0.27

Price$1.29

Change-0.77%

Shares Out4.48M

Market Cap$5.78M

Enterprise Value$-1.81M

52W Range0.84 - 2.68

Beta0.19

P/E-0.64

P/B1.00

P/FCF-0.84

EV/EBITDA0.20

EV/FCF0.27

Earnings Yield-157.45%

FCF Yield-118.45%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio1.31

Quick Ratio1.31

Volume8.71K

Avg Volume128.47K

EPS Surprise-0.05

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

84/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

60/100

Why this score▼

Manageable debt level · 0Healthy liquidity · 1.31Weak profitability

Analyst view

Analyst sentiment and price target

ALZN

Analyst sentiment

Based on 2 analyst votes · 2026-10-20

100/100

Bullish

Hold

Bearish

Company Overview

IPO: 6/15/2021

Industry: Biotechnology

P/B i: 1.00

Debt / Equity i: 0.00

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score17 / 20

Debt / Equity: 0.00

Current Ratio: 1.31

Quick Ratio: 1.31

Status: Strong

Insider Transactions

Recent executive and insider activity

⚠ 1 high-volume insider sell detected

AULT MILTON C III

Transaction: 08/26/2026

SELL

Change

-2,000

Price

$1.56

Filing

08/31/2026

Type

SELL

AULT MILTON C III

Transaction: 04/14/2026

BUY

Change

+2,000

Price

$1.03

Filing

08/31/2026

Type

BUY

AULT MILTON C III

Transaction: 07/31/2026

BUY

Change

+7,500

Price

Not reported

Filing

08/04/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
AULT MILTON C III	SELL	-2,000	$1.56	08/26/2026	08/31/2026
AULT MILTON C III	BUY	+2,000	$1.03	04/14/2026	08/31/2026
AULT MILTON C III	BUY	+7,500	Not reported	07/31/2026	08/04/2026
Hyperscale Data, Inc.	BUY	+7,500	Not reported	07/31/2026	08/04/2026
Katzoff David J	BUY	+300,000	$2.33	04/17/2026	08/04/2026
Jackman Stephan	BUY	+450,000	$2.33	04/17/2026	08/04/2026
GUSTAFSON MARK	BUY	+60,000	$2.33	04/17/2026	08/04/2026
Oram Jeffrey	BUY	+60,000	$2.33	04/17/2026	08/04/2026
Horne William B.	BUY	+60,000	$2.33	04/17/2026	08/04/2026
AULT MILTON C III	BUY	+100,000	$2.33	04/17/2026	08/04/2026
Nisser Henry Carl	BUY	+60,000	$2.33	04/17/2026	08/04/2026
Hyperscale Data, Inc.	OTHER	+1,111	$108.00	10/30/2024	08/04/2026
Hyperscale Data, Inc.	OTHER	+988	$4050.00	04/26/2022	08/04/2026
AULT MILTON C III	BUY	+108,388	$1.00	04/14/2026	04/16/2026
AULT MILTON C III	SELL	-1,851	$2.07	12/23/2025	12/30/2025
Horne William B.	SELL	-3,333	$2.12	12/19/2025	12/23/2025
McGrath Lynne Fahey	SELL	-30	$2.29	10/23/2025	10/24/2025
AULT MILTON C III	SELL	-20,397	$2.32	10/09/2025	10/10/2025
AULT MILTON C III	SELL	—	$2.32	10/08/2025	10/10/2025
AULT MILTON C III	SELL	-101,394	$2.44	10/08/2025	10/10/2025

About the Company

Alzamend Neuro Inc

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Source - link

Peers

ACXP ADIL APRE BCDA CDIO CELZ HCWB KPRX NRSN PHIO

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?

Alzamend Neuro (ALZN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026 in Washington, DC Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial ATLANTA, Aug. 20, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that an abstract reporting resting-state functional magnetic resonance imaging ("fMRI") findings for AL001, Alzamend's novel organic lithium salt, has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience ("SfN"), to be held November 14–18, 2026 in Washington, DC. The abstract, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," will be presented as a poster in the Neuropsychiatric Disorders session (Session PSTR337) on Wednesday, November 18, 2026, from 8:00 a.m.

PRNewsWire

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain Presentation will report first-of-its-kind pharmacokinetic imaging results from Phase 1/2A trial of AL001, Alzamend's novel organic lithium drug candidate, in healthy human subjects ATLANTA, Aug. 18, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that an abstract reporting pharmacokinetic imaging data for AL001, Alzamend's novel organic lithium salt, has been accepted for oral presentation at the International Society for Magnetic Resonance in Medicine ("ISMRM") Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR, to be held from September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain. The abstract, titled "Pharmacokinetics Imaging of Lithium at 7T – Results from a Phase 1/2A Clinical Trial with a Novel Organic Lithium Salt" (Abstract #00047), was selected following a competitive review by the workshop's organizing committee and will be presented in the "Proffered Papers" oral session on Tuesday, September 29, 2026 at 1:35 PM local time.

PRNewsWire

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock Agreement provides for up to $17.5 million in additional funding through subsequent tranche closings to support Alzamend's clinical programs and working capital needs ATLANTA, Aug. 4, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), announced today that it has entered into a Securities Purchase Agreement (the "Agreement") with Ault Lending, LLC ("Ault Lending"), pursuant to which Ault Lending has agreed to purchase up to $25,000,000 of the Company's newly designated Series D Convertible Preferred Stock (the "Preferred Shares"), and closed on the initial tranche in the amount of $7.5 million. Under the terms of the Agreement, Ault Lending agreed to purchase up to 25,000 Preferred Shares at a purchase price of $1,000 per share, for an aggregate purchase price of $25,000,000, with each Preferred Share having a stated value of $1,050.

PRNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-03-11	-0.53	-0.58	-0.05
2025-12-09	-0.83	-0.3	0.53
2025-09-10	-3.69	-1.28	2.41
2025-03-10	-2.61	-1.71	0.9
2024-12-11	-21.42	-3.6	17.82
2024-09-11	-2.38	-11.25	-8.87
2024-07-30	-2.75	-13.35	-10.6
2024-03-25	-0.32	-34.2	-33.88
2023-12-15	-0.67	39.6	40.27
2023-09-13	-47.23073	-53.98	-6.74927
2023-07-27	-30.36076	-40.48	-10.11924
2023-03-15	-0.04	-0.06	-0.02